Uno studio di fase III per valutare la sicurezza e l'immunogenicità di una vaccinazione di richiamo candidata di HIPRA contro COVID-19.
Uno studio di fase III, in aperto, a braccio singolo, multicentrico, per valutare la sicurezza e l'immunogenicità di una vaccinazione di richiamo con un candidato eterodimero di fusione proteica ricombinante RBD (PHH-1V) contro SARS-CoV-2, in adulti vaccinati contro COVID -19.
This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adults vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine at least 91 days before day 0. All the participants will receive a booster dose of the HIPRA's COVID-19 Vaccine and will be followed for 26 weeks or 52 weeks if they participate in the safety cohort, or the immunogenicity cohort, respectively.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Milano
-
Milan, Milano, Italia, 20162
- Hospital de Niguarda
-
-
-
-
BARCELONA
-
Badalona, BARCELONA, Spagna, 08916
- Hospital Germans Trias I Pujol
-
Barcelona, BARCELONA, Spagna, 08035
- Hospital Vall Hebron
-
-
Barcelona
-
Barcelona, Barcelona, Spagna, 08023
- Hospital HM Delfos
-
Barcelona, Barcelona, Spagna, 08023
- Hospital Quironsalud Barcelona
-
Mollet del Vallès, Barcelona, Spagna, 08100
- Hospital de Mollet
-
-
Girona
-
Girona, Girona, Spagna, 17007
- Hospital Universitari Dr. Josep Trueta
-
-
Madrid
-
Madrid, Madrid, Spagna, 28046
- Hospital Universitario La Paz
-
Madrid, Madrid, Spagna, 28007
- Hospital Gregorio Marañón
-
Madrid, Madrid, Spagna, 28050
- Hospital HM Sanchinarro
-
Madrid, Madrid, Spagna, 28660
- Hospital HM Montepríncipe
-
Madrid, Madrid, Spagna, 28223
- Hospital Quironsalud Madrid
-
Meco, Madrid, Spagna, 28805
- Hospital Principe de Asturias
-
Móstoles, Madrid, Spagna, 28938
- Hospital HM Puerta del Sur
-
-
Málaga
-
Málaga, Málaga, Spagna, 29010
- Hospital Regional Universitario de Málaga
-
-
Spain
-
Barcelona, Spain, Spagna, 17170
- Hospital Clinic de Barcelona
-
-
VIZCAYA
-
Barakaldo, VIZCAYA, Spagna, 48903
- Hospital de Cruces
-
-
Valencia
-
Valencia, Valencia, Spagna, 46010
- Hospital Clínico de Valencia
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female, ≥ 16 years old at Day 0.
- Willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures.
- Have a recognized primary vaccination scheme recognized by the authorities with Comirnaty, Spikevax, Vaxevria or Janssen at least 91 days and preferably a maximum of 240 days before Day 0.
- If having an underlying illnesses must be stable and well-controlled according to the investigator judgment.
- Participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine.
- Participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination.
- Female participant of childbearing potential must have a negative pregnancy test on the on Day 0 prior to vaccination.
- Female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom).
- Male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence).
- Male participants must refrain from donating sperm for at least 28 days after day 0.
Exclusion Criteria:
- History of anaphylaxis to any prior vaccine.
- Previous severe SARS-CoV-2 infections that required >24 hous of hospitalisation.
- Participant received or plans to receive live attenuated vaccines within 4 weeks before and after day 0; or other not live vaccines within 14 days before and after day 0.
- Pregnancy or breast-feeding at screening or Day 0 or willingness/intention to become pregnant during the study.
- Having a clinically significant acute illness or fever (temperature ≥38º C (100.4ºF)) at screening or within 48 hours prior to Day 0.
- Participant had a surgery requiring hospitalization before vaccination and he/she has not received the hospital discharge at day 0; or has a surgery requiring hospitalization planned within 12 weeks after study vaccine administration.
- Having any active malignancy even if under treatment except for non-melanoma skin cancer, uterine cervical carcinoma, anal carcinoma, localized prostate cancer.
- Having ongoing severe and non-stable psychiatric condition likely to affect participation in the study.
- Having problematic or risk use of substances including alcohol that can compromise the study follow-up.
- Having a bleeding disorder or has any condition that in the opinion of the investigator contraindicates intramuscular injections.
- Having abnormal function of the immune system, except stable clinical conditions like controlled HIV.
- Having clinically significant and unstable cardiovascular, respiratory, hepatic, neurological, gastrointestinal, renal, or any other medical disorder judged by the investigator within 3 months before screening.
- Chronic or recurrent administration of systemic immunosuppressant medication.
- Having received immunoglobulins and/or blood-derived products 12 weeks prior vaccination (Day 0) or expects to receive them during the study.
- Having received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat COVID-19 within 90 days before day 0.
- Participation in any research involving an investigational product (drug, biologic, device) within 12 weeks prior to vaccination and during the study.
- Participant has donated ≥ 450ml of blood products within 12 weeks before screening.
- Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Experimental: COVID-19 Vaccine HIPRA 40 ug/dose
COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA |
Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)
Lasso di tempo: Day 7
|
Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination. |
Day 7
|
|
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (AEs)
Lasso di tempo: Day 28
|
Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through Day 28 after vaccination |
Day 28
|
|
Incidence of Serious Adverse Events (Safety and tolerability) (SAE)
Lasso di tempo: Day 365
|
Number and percentage of serious adverse events (SAEs) through the end of the study. |
Day 365
|
|
Incidence of Special Interest Adverse Events (Safety and tolerability) (AESI).
Lasso di tempo: Day 365
|
Number and percentage of adverse event of special interest (AESI) through the end of the study. |
Day 365
|
|
Incidence of Medically Attended Adverse Events (Safety and tolerability) (MAAEs)
Lasso di tempo: Day 365
|
Number and percentage of medically attended adverse events (MAAE) related to study vaccine through the end of the study. |
Day 365
|
|
Incidence of Adverse Events in laboratory parameters (Safety and tolerability)
Lasso di tempo: Day 365
|
Grade 3 and 4 changes from baseline in safety laboratory parameters at Days 14, 91 and 182 after vaccination. through the end of the study. |
Day 365
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Changes in the immunogenicity measured by pseudovirus neutralisation
Lasso di tempo: Day 365
|
Neutralisation titre against Wuhan and Omicron strains, and any other relevant VOC in the epidemiologic moment, measured as inhibitory concentration 50 (IC50) by a pseudovirion-based neutralisation assay (PBNA) and reported as reciprocal concentration for each individual sample and geometric mean titre (GMT) for descriptive statistics analysis at Baseline and at Days 14, 91, 182 and 365. |
Day 365
|
|
Changes in the immunogenicity measured by pseudovirus neutralisation
Lasso di tempo: Day 14
|
The geometric mean fold rise (GMFR) in neutralising antibody titre from baseline to Day 14. |
Day 14
|
|
Changes in the immunogenicity measured by means of total antibody against RBD
Lasso di tempo: Day 365
|
Binding antibodies titre measured for each individual sample and GMT for descriptive statistics analysis at Baseline and Days 14, 91, 182 and 365. |
Day 365
|
|
Changes in the immunogenicity measured by means of total antibody against RBD.
Lasso di tempo: Day 14
|
The geometric mean fold rise (GMFR) in binding antibody titre from baseline to Day 14. |
Day 14
|
|
Changes in the immunogenicity measured by means of total antibody against RBD
Lasso di tempo: Day 14
|
The percentage of subjects that after the booster dose have a ≥4-fold change in binding antibodies titre from Baseline to Day 14. |
Day 14
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To assess number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Lasso di tempo: Day 365
|
Number and percentage of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster according to COVID-19 infection criteria throughout the study duration. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Lasso di tempo: Day 365
|
Number and percentage of COVID-19 severe infections ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V and hospital admissions SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Lasso di tempo: Day 365
|
Number and percentage of hospital admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V in ICU. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Lasso di tempo: Day 365
|
Number and percentage of intensive care unit (ICU) admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V receiving noninvasive ventilation. SARS-CoV-2 infections ≥14 days after PHH-1V booster.
Lasso di tempo: Day 365
|
Number and percentage of noninvasive ventilation administration associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V causing death.
Lasso di tempo: Day 365
|
Number and percentage of deaths associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study. |
Day 365
|
|
To evaluate T-cell mediated responses against the SARS-CoV-2 S glycoprotein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster..
Lasso di tempo: Day 14
|
T-cell-mediated response to the SARS-CoV-2 S protein as measured by whole peripheral blood mononuclear cell (PBMC) stimulation by enzyme-linked immune absorbent spot (ELISpot) at Baseline and at Day 14. This analysis will be performed in 30 subjects. |
Day 14
|
|
To assess Th-1/Th-2 T-cell mediated responses against S protein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster.
Lasso di tempo: Day 14
|
CD4+/CD8+ T-cell response to the SARS-CoV-2 S protein as measured by in vitro PBMC stimulation by cytokine staining assays at Baseline and at Day 14. This analysis will be performed in 30 subjects. |
Day 14
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Teresa Prat, HIPRA SICENTIFIC S.L.U
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Infezioni delle vie respiratorie
- Infezioni
- Infezioni da virus a RNA
- Malattie virali
- Malattie delle vie respiratorie
- Malattie polmonari
- Polmonite, virale
- Polmonite
- Infezioni da coronavirus
- Infezioni da Coronaviridae
- Infezioni da Nidovirus
- COVID-19
- Prodotti biologici
- Miscele complesse
- Vaccini
- Vaccini virali
- Vaccini contro il covid-19
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- HIPRA-HH-5
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .